专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070015707A1 Neuroprotective effect of activin in animals exposed to hypoxia/ischemia 审中-公开
标题翻译：激活素在缺氧/缺血的动物中的神经保护作用
公开(公告)号：US20070015707A1
公开(公告)日：2007-01-18
申请号：US11493883
申请日：2006-07-26
申请人： Peter Gluckman , Christopher Williams , Dahao Wu , Paul Hughes , Maggie Lai
发明人： Peter Gluckman , Christopher Williams , Dahao Wu , Paul Hughes , Maggie Lai
IPC分类号： A61K38/17
CPC分类号： A61K38/22
摘要： This invention includes embodiments comprising activin and analogs of activin for neuronal rescue in patients having neurons that are subject to death and/or degradation as a result of neurological diseases. In certain embodiments, an activin receptor agonist can be useful for treating neuralogical diseases such as Alzheimer's Disease, Parkinson's Disease or other diseases involving neural degeneration and loss of neural function.
摘要翻译：本发明包括包含激活素和活化素类似物的实施方案，用于在患有由于神经疾病导致的死亡和/或降解的神经元的患者中进行神经元拯救。在某些实施方案中，激活素受体激动剂可用于治疗诸如阿尔茨海默病，帕金森氏病或涉及神经变性和神经功能丧失的其它疾病的神经疾病。

2. 发明申请

US20060281675A1 Somatogenic therapy using a 20kda placental variant of growth hormone 审中-公开
标题翻译：使用生长激素的20kda胎盘变体的生长激素治疗
公开(公告)号：US20060281675A1
公开(公告)日：2006-12-14
申请号：US10568573
申请日：2004-08-19
申请人： Peter Gluckman , Robert Gilmour , Mark Vickers , Bernhard Breier
发明人： Peter Gluckman , Robert Gilmour , Mark Vickers , Bernhard Breier
IPC分类号： A61K38/27
CPC分类号： A61K38/27
摘要： Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties are reduced or eliminated. In particular, it is directed at a method of treatment whereby the lactogenic side effects of hGH treatment are reduced. Said enhanced method includes the use of a growth hormone variant; 20 kDa hGH-V in the treatment of conditions that are currently treated with hGH or that have the potential to be treated with hGH.
摘要翻译：本发明的实施方案提供治疗需要人生长激素（hGH）治疗的条件的改进方法，由此保留hGH的有益作用，例如生长促进和脂肪分解，并减少或消除不需要的性质。特别地，本发明涉及一种治疗方法，其中hGH治疗的泌乳期副作用降低。所述增强方法包括使用生长激素变体; 20 kDa hGH-V治疗目前用hGH治疗或有可能用hGH治疗的病症。

3. 发明授权

US06204240B1 TGF-&bgr;1 to improve neural outcome 失效
标题翻译： TGF-β1改善神经结局
公开(公告)号：US06204240B1
公开(公告)日：2001-03-20
申请号：US08232118
申请日：1994-05-02
申请人： Peter Gluckman , Karoly Nikolics , Christopher Williams
发明人： Peter Gluckman , Karoly Nikolics , Christopher Williams
IPC分类号： A61K3818
CPC分类号： A61K38/1841
摘要： The invention relates to methods of treating injuries to or diseases of the central nervous system which methods involve increasing the active concentration(s) of transforming growth factor beta 1 (TGF-&bgr;1) and/or analogues thereof in the central nervous system of the patient. The present invention also provides pharmaceutical compositions comprising TGF-&bgr;1 and/or analogues thereof for administration to a patient prior to, simultaneous with, or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.
摘要翻译：本发明涉及治疗中枢神经系统损伤或疾病的方法，该方法包括增加患者的中枢神经系统中转化生长因子β1（TGF-β1）和/或其类似物的活性浓度。本发明还提供包含TGF-β1和/或其类似物的药物组合物，用于在神经损伤之前，同时或之后向患者施用，所述组合物可用于最小化对中枢神经系统的损伤侮辱

4. 发明授权

US6034059A Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients 失效
标题翻译：使用正确的IGF-1和低热量的营养物治疗分解代谢状态
公开(公告)号：US6034059A
公开(公告)日：2000-03-07
申请号：US979863
申请日：1993-03-17
申请人： Linda Fryklund , Peter Gluckman , Anna Skottner
发明人： Linda Fryklund , Peter Gluckman , Anna Skottner
IPC分类号： A61K38/27 , A61K38/30 , A61P3/00 , A61P43/00 , A61K38/00 , A61K38/18
CPC分类号： A61K38/30
摘要： IGF-1 and a hypocaloric amount of nutrient are used to treat a catabolic state in a patient. The IGF-1 and nutrient can be administered simultaneously, separately or sequentially. The amounts of IGF-1 and hypocaloric amount of nutrient are effective for the treatment of the catabolic state.
摘要翻译： PCT No.PCT / SE91 / 00557 Sec。 371日期1993年3月17日 102（e）1993年3月17日PCT 1991年8月22日PCT公布。出版物WO92 / 03154 日期：1993年3月5日IGF-1和低热量的营养物质用于治疗患者的分解代谢状态。 IGF-1和营养素可以同时，分开或依次给药。 IGF-1和低热量的营养素的量对于分解代谢状态的治疗是有效的。

5. 发明授权

US5434134A Use of human IGF-1 to treat cardiac disorders 失效
标题翻译：使用人类IGF-1治疗心脏疾病
公开(公告)号：US5434134A
公开(公告)日：1995-07-18
申请号：US084232
申请日：1993-10-07
申请人： Peter Gluckman , Anna Skottner
发明人： Peter Gluckman , Anna Skottner
IPC分类号： A61K38/27 , A61K38/30 , A61P9/00 , A61P9/08 , A61P9/10 , A61K38/00 , A61K38/08 , C07K14/00
CPC分类号： A61K38/30
摘要： Human IGF-I or effective analogues thereof are used for preventing or treating cardiac disorders. Compositions are also provided that comprise human IGF-I or effective analogues thereof together with additional proteins or peptides such as other growth factors, hormones, binding proteins or receptors for enhancing or improving the desired effects of IGF-I or its effective analogues and possibly pharmaceutically acceptable carrier or diluent for the prevention or treatment of cardiac disorders.
摘要翻译： PCT No.PCT / SE92 / 00009 Sec。 371日期：1993年10月7日 102（e）日期1993年10月7日PCT 1992年1月10日提交PCT公布。出版物WO92 / 11865 1992年7月23日，人IGF-I或其有效类似物用于预防或治疗心脏病。还提供了组合物，其包含人IGF-1或其有效类似物以及另外的蛋白质或肽，例如其它生长因子，激素，结合蛋白或受体，用于增强或改善IGF-1或其有效类似物以及可能的药学上的期望作用用于预防或治疗心脏疾病的可接受的载体或稀释剂。

6. 发明授权

US5276014A Treatment of human lactation failure 失效
标题翻译：治疗人类哺乳期失败
公开(公告)号：US5276014A
公开(公告)日：1994-01-04
申请号：US765171
申请日：1991-09-26
申请人： Peter Gluckman , Stella R. Milsom
发明人： Peter Gluckman , Stella R. Milsom
IPC分类号： A61K31/165 , A61K31/215 , A61K38/22 , A61K38/27 , A61P1/16 , A61P15/14 , A61P43/00 , A61K37/02 , A61K31/475 , A61K37/36 , A61K37/43
CPC分类号： A61K38/27 , A61K31/475 , A61K38/25 , A61K38/30
摘要： The invention relates to the use of hGH, hGRF, hIGF-1, hIGF-2 or analogs of these or a mixture of two or more of these, alone or in conjunction with lactational enhancers for the treatment of human lactation failure. It also relates to the use of hGH, hGRF, hIGF-1, hIGF-2 or analogs of these or a mixture of two or more of these, alone or in conjunction with lactational enhancers for the manufacturing of a medicament for the treatment of human lactation failure, also a profphlactic treatment. Preferably human growth hormone is used. The invention also relates to a method for the treatment of human lactation failure as well as compositions and methods for their manufacturing.
摘要翻译：本发明涉及hGH，hGRF，hIGF-1，hIGF-2或它们的类似物或它们中的两种或更多种的混合物，单独或与泌乳增强剂联合用于治疗人类哺乳期衰竭。它还涉及hGH，hGRF，hIGF-1，hIGF-2或它们的类似物或它们中的两种或更多种的混合物，单独使用或与泌乳增强剂联合用于制备用于治疗人的药物哺乳期失败，也是一种表面处理。优选使用人生长激素。本发明还涉及一种用于治疗人类哺乳期失败的方法以及其制备的组合物和方法。

7. 发明申请

US20070224165A1 Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion 审中-公开
标题翻译：静脉注射后Gly-Pro-Glu的神经保护作用
公开(公告)号：US20070224165A1
公开(公告)日：2007-09-27
申请号：US10574280
申请日：2004-10-22
申请人： Jian Guan , Gregory Thomas , David Batchelor , Peter Gluckman
发明人： Jian Guan , Gregory Thomas , David Batchelor , Peter Gluckman
IPC分类号： A61K38/06
CPC分类号： A61K38/06 , A61K2300/00
摘要： Gly-Pro-Glu (GPE) is rapidly metabolized in vivo. We found that GPE infusion elicits potent and consistent neuroprotection in all brain regions examined, and in certain embodiments, the effects were greater than those of a bolus injection followed by infusion (“loading dose/infusion”). GPE reduced apoptosis in the hippocampus and inhibited microglial proliferation and prevented the injury-induced loss of astrocytes and improved long-term somatofunction. GPE after infusion showed a broad effective dose range (0.3-30 mg/kg/h) and had a surprisingly extended window of treatment efficacy, permitting its use from 1 to at least as late as 24 h after neural injury. We also found that neuroprotective effects of acute GPE administration were prolonged and therefore capable of being used effectively to treat a variety of neurodegenerative conditions, even when administered after a neural injury. Thus, GPE can be an effective neuroprotective agent used either alone or co-administered along with other neuroprotective agents, antiinflammatory agents or peptidase or protease inhibitors. Compositions of GPE and protease and/or peptidase inhibitors are provided.
摘要翻译： Gly-Pro-Glu（GPE）在体内迅速代谢。我们发现GPE输注在所检查的所有脑区域中引起有效和一致的神经保护作用，并且在某些实施方案中，效果大于进行推注，随后输注（“加载剂量/输注”）的效果。 GPE减少海马细胞凋亡并抑制小胶质细胞增殖，并防止损伤诱导的星形胶质细胞的丧失和改善长期的生物功能。输注后的GPE显示广泛的有效剂量范围（0.3-30mg / kg / h），并且具有惊人的延长的治疗效果窗口，允许其在神经损伤后至少至迟24小时使用。我们还发现，急性GPE给药的神经保护作用延长，因此即使在神经损伤后施用，也能有效地用于治疗各种神经退行性疾病。因此，GPE可以是单独使用或与其它神经保护剂，抗炎剂或肽酶或蛋白酶抑制剂一起使用的有效的神经保护剂。提供GPE和蛋白酶和/或肽酶抑制剂的组合物。

8. 再颁专利

USRE43982E1 IGF-1 to improve neural outcome 有权
标题翻译： IGF-1改善神经结局
公开(公告)号：USRE43982E1
公开(公告)日：2013-02-05
申请号：US10606745
申请日：2003-06-27
申请人： Peter Gluckman , Karoly Nikolich
发明人： Peter Gluckman , Karoly Nikolich
IPC分类号： A61K38/30
摘要： A method of treating injuries to or diseases of the central nervous system that predominantly effects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.
摘要翻译：治疗主要影响神经胶质细胞和/或非胆碱能神经细胞的中枢神经系统的损伤或疾病的方法，其特征在于其包括增加胰岛素样生长因子1和/或在患者的中枢神经系统中的类似物。本发明还提供包含胰岛素样生长因子1和/或其类似物的治疗组合物，用于在神经损伤或神经损伤时向患者施用，所述组合物可用于最小化在侮辱之后发生的对中枢神经系统的损伤。

9. 发明授权

US07112570B2 GPE analogs 失效
标题翻译： GPE类似物
公开(公告)号：US07112570B2
公开(公告)日：2006-09-26
申请号：US10362266
申请日：2001-08-24
申请人： Peter Gluckman , Tajrena Alexi
发明人： Peter Gluckman , Tajrena Alexi
IPC分类号： A61K38/06 , C07K5/083
CPC分类号： C07K5/0819 , A61K38/00 , A61K47/60 , C07K5/0806
摘要： The invention relates to GPE analogs, particularly GPE analogs capable of inducing an equivalent physiological effect to GPE within a patient. Such GPE analogs include peptides where the Gly of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Pro; where the Pro of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Gly; and where the Glu of Gly-Pro-Glu is replaced by any of Asn, Asp, or Gln. The GPE analogs of the invention have application in any method of therapy or prophylaxis in which GPE has application. These applications include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS. The GPE analogs will normally be administered as part of a pharmaceutical composition or preparation.
摘要翻译：本发明涉及GPE类似物，特别是GPE类似物，其能够诱导患者内GPE的等效生理作用。这样的GPE类似物包括其中Gly-Pro-Glu的Gly被Ala，Ser，Thr或Pro中的任一个替代的肽; 其中Gly-Pro-Glu的Pro被Ala，Ser，Thr或Gly中的任一个替代; 并且其中Gly-Pro-Glu的Glu被Asn，Asp或Gln中的任一个替代。本发明的GPE类似物可应用于GPE具有应用的任何治疗或预防方法。这些应用包括治疗急性脑损伤和神经变性疾病，包括但不限于CNS中的损伤或疾病。 GPE类似物通常作为药物组合物或制剂的一部分施用。

10. 发明申请

US20070298009A1 Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration 有权
标题翻译：甘氨酰-2-甲基脯氨酰谷氨酸对神经变性的影响
公开(公告)号：US20070298009A1
公开(公告)日：2007-12-27
申请号：US11314424
申请日：2005-12-20
申请人： Peter Gluckman , Gregory Thomas , Jian Guan , Michael Dragunow , Ashmit Anand , Nicole de Rosbo , Frank Sieg , Margaret Brimble
发明人： Peter Gluckman , Gregory Thomas , Jian Guan , Michael Dragunow , Ashmit Anand , Nicole de Rosbo , Frank Sieg , Margaret Brimble
IPC分类号： A61K31/40 , A61K31/426 , A61K31/435 , A61K31/47 , A61K31/498 , A61K31/5375 , A61K38/18 , A61K38/20 , A61K38/21 , A61K39/395 , A61P25/08 , A61P25/28
CPC分类号： A61K31/40 , A61K31/426 , A61K31/435 , A61K31/47 , A61K31/498 , A61K31/5375 , A61K38/06 , A61K45/06 , A61K2300/00
摘要： This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
摘要翻译：本发明提供甘氨酰-L-脯氨酰基-L-谷氨酸（GPE）的类似物和肽模拟物。特别地，本发明涉及抗细胞凋亡，抗坏死和具有神经保护作用的GPE类似物和肽模拟物。这些药物可用于治疗由毒素，创伤性脑损伤和脑的自身免疫性疾病如多发性硬化和减少癫痫发作引起的神经变性和行为障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式